EUVIMEDEUVIMED entdecken
Crossref

Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial)

Takayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, Takashi Takeshita, Yuichiro Kikawa, Kokoro Kobayashi, Nobutaka Iwakuma, Takuho Okamura, Takayuki Kobayashi, Yuriko Katagiri, Masahiro Kitada, Nobumoto Tomioka und 6 weitere

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07414-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Takayuki Iwamoto und 17 weiteren Autor:innen. Beteiligte Einrichtung: Breast and Thyroid Surgery, Kawasaki Medical School Hospital, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan. tiwamoto@med.kawasaki-m.ac.jp. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Recurrence, Local, Erb-b2 Receptor Tyrosine Kinases, Receptors, Estrogen. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Pfizer Inc., AstraZeneca United States.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study aimed to determine whether the 21-Gene Breast Recurrence Score® assay from primary breast tissue predicts the prognosis of patients with hormone receptor-positive and human epidermal growth factor 2-negative advanced breast cancers (ABCs) treated with fulvestrant monotherapy (Group A) and the addition of palbociclib combined with fulvestrant (Group B), which included those who had progression in Group A from the Japan Breast Cancer Research Group-M07 (FUTURE trial). METHODS: Progression-free survival (PFS) and overall survival (OS) were compared using the log-rank test and Cox regression analysis based on original recurrence score (RS) categories (Low: 0-17, Intermediate: 18-30, High: 31-100) by treatment groups (A and B) and types of ABCs (recurrence and de novo stage IV). RESULTS: In total, 102 patients [Low: n = 44 (43.1%), Intermediate: n = 38 (37.5%), High: n = 20 (19.6%)] in Group A, and 45 in Group B, who had progression in Group A were analyzed. The median follow-up time was 23.8 months for Group A and 8.9 months for Group B. Multivariate analysis in Group A showed that low-risk [hazard ratio (HR) 0.15, 95% confidence interval (CI) 0.04-0.53, P = 0.003] and intermediate-risk (HR 0.22, 95% CI 0.06-0.78) with de novo stage IV breast cancer were significantly associated with better prognosis compared to high-risk. However, no significant difference was observed among patients with recurrence. No prognostic significance was observed in Group B. CONCLUSION: We found a distinct prognostic value of the 21-Gene Breast Recurrence Score® assay by the types of ABCs and a poor prognostic value of the high RS for patients with de novo stage IV BC treated with fulvestrant monotherapy. Further validations of these findings are required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasm Recurrence, LocalErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenHumansFemaleMiddle AgedPrognosisAgedJapanAdultAntineoplastic Combined Chemotherapy ProtocolsFulvestrantReceptors, ProgesteroneBiomarkers, TumorPyridinesPiperazinesNeoplasm Staging

Stichwörter der Autor:innen

21-Gene Breast Recurrence Score® assayBiomarkerBreast cancer recurrenceDe novo stage IV breast cancerFulvestrantPalbociclib

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenFulvestrantReceptors, ProgesteroneBiomarkers, TumorPyridinesPiperazinesERBB2 protein, humanpalbociclib

Autor:innen und Institutionen

  • Breast and Thyroid Surgery, Kawasaki Medical School Hospital, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan. tiwamoto@med.kawasaki-m.ac.jp.
  • Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan. tiwamoto@med.kawasaki-m.ac.jp.
  • Department of Breast Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
  • Breast Surgery, Hokkaido Cancer Center, Sapporo, Hokkaido, Japan.
  • Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Kumamoto, Japan.
  • Department of Breast Surgery, Kansai Medical University Hospital, Hirakata, Osaka, Japan.

Förderung

  • Pfizer Inc.
  • AstraZeneca United States

Zitieren

APA

Iwamoto, T., Niikura, N., Watanabe, K., Takeshita, T., Kikawa, Y., Kobayashi, K., Iwakuma, N., Okamura, T., Kobayashi, T., Katagiri, Y., Kitada, M., Tomioka, N., Miyoshi, Y., Shigematsu, H., Miyashita, M., Ishiguro, H., Masuda, N., & Saji, S. (2024). Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial). Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07414-7

Vancouver

Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K, et al. Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial). Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07414-7

BibTeX
@article{Iwamoto2024,
  author = {Iwamoto, Takayuki and Niikura, Naoki and Watanabe, Kenichi and Takeshita, Takashi and Kikawa, Yuichiro and Kobayashi, Kokoro and Iwakuma, Nobutaka and Okamura, Takuho and Kobayashi, Takayuki and Katagiri, Yuriko and Kitada, Masahiro and Tomioka, Nobumoto and Miyoshi, Yasuo and Shigematsu, Hideo and Miyashita, Minoru and Ishiguro, Hiroshi and Masuda, Norikazu and Saji, Shigehira},
  title = {Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial)},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07414-7}
}
Kostenlos starten →